Immunoassay Market - Global Forecast 2025-2032

The immunoassay market is undergoing rapid transformation, powered by technological innovation and evolving healthcare needs. Senior executives navigating this sector will find themselves at the center of a dynamic landscape where clinical demand meets next-generation diagnostic capabilities.

Market Snapshot: Growth and Trajectory in the Immunoassay Market

The immunoassay market grew from USD 28.29 billion in 2024 to USD 30.38 billion in 2025. Sustained by a compound annual growth rate (CAGR) of 7.37%, it is projected to reach USD 49.98 billion by 2032. This trajectory is catalyzed by the integration of automated platforms, digital analytics, and the increasing necessity for precise biomarker detection in diagnostics, research, and healthcare management. The primary keyword, immunoassay market, underpins this expansion, reflecting the sector’s essentiality in shaping modern diagnostics and personalized medicine.

Scope & Segmentation: Comprehensive View of Technologies, Applications, and Geography

• Type: Qualitative immunoassays, Quantitative immunoassays
• Technology: Enzyme immunoassays, Enzyme-linked immunosorbent assay, Fluorescent immunoassay, Lateral flow assay, Radioimmunoassay, Western blot
• Instruments: Analyzers & kits, Biosensors, Microfluidic devices, Microplates, PCR devices, Reagents (antibodies, antigens, blocking reagents, buffers & standards, enzymes, substrates), Software & services
• Sample Types: Blood, saliva, tissue, urine
• Detection Modes: Chemiluminescent, colorimetric, fluorometric, radioisotopic
• Application Areas: Allergy, autoimmune diseases, cardiology, endocrinology, infectious diseases, oncology, toxicology (drug screening, environmental testing)
• End Users: Contract research organizations, diagnostic laboratories, hospitals & clinics, pharmaceutical & biotechnology companies, research institutions
• Deployment Types: Laboratory tests, point-of-care tests
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Companies Covered: Abbott Laboratories, Agilent Technologies, Almac Group, ANP Technologies, Autobio Diagnostics, Becton Dickinson, Bio-Rad Laboratories, Bio-Techne, BioLegend, bioMérieux, Biosurfit, Boditech Med, Charles River Laboratories, Danaher, Diasorin, Dynex Technologies, Epitope Diagnostics, Roche, Fapon Biotech, Gyros Protein Technologies, H.U. Group Holdings, J. Mitra, Kamiya Biomedical, Philips, Merck, MiCo BioMed, NanoEntek, Nanōmix, OPKO Health, Promega, QIAGEN, Quanterix, QuidelOrtho, Randox Laboratories, Revvity, Sekisui Diagnostics, Shenzhen Micropoint, Shenzhen Mindray, Siemens Healthineers, Sysmex, Tecan, Thermo Fisher, Tosoh Corporation, WAK-Chemie Medical, Zoetis, Zybio

Key Takeaways: Strategic Insights for Senior Decision-Makers

• Immunoassay platforms are transitioning to fully automated, high-throughput systems, reducing manual intervention and operational bottlenecks in laboratories.
• Development of multiplex and digital immunoassay technologies enhances the capacity for simultaneous biomarker analysis and real-time patient insights.
• Microfluidic platforms and portable devices are supporting decentralized diagnostics, catering to the growing demand for point-of-care and near-patient testing.
• Adoption of artificial intelligence and advanced analytics enables predictive insights for patient stratification and improved clinical decision-making.
• Regional dynamics reveal diverse growth drivers: mature healthcare infrastructure and innovation funding propel adoption in the Americas and Europe, while Asia-Pacific and select African and Middle Eastern markets focus on laboratory expansion and technology transfer.
• Leading companies are leveraging strategic partnerships and portfolio diversification to strengthen market presence and respond to evolving clinical and regulatory environments.

Tariff Impact: Navigating Policy-Driven Supply Chain Complexities

Recent United States tariff measures have introduced heightened supply chain complexity for immunoassay manufacturers. This policy shift has driven reevaluations in sourcing, cost management, and inventory planning. Some firms are expanding domestic operations or seeking alternative partners in untaxed regions, while others are optimizing procurement strategies and communicating transparently with clients to mitigate further risk exposure and maintain supply continuity.

Methodology & Data Sources

This report was developed using a phased methodology: comprehensive secondary research, expert interviews with industry stakeholders, and rigorous triangulation of qualitative and quantitative data. Cross-functional peer review and scenario validation ensured the reliability of all findings.

Why This Report Matters

• Enables business leaders to make informed investments and innovation decisions based on robust, segment-specific insights.
• Offers clarity on global drivers, regional opportunities, and competitive strategies for scalable market growth.
• Equips procurement and R&D leaders to adapt to regulatory shifts and manage supply chain risks effectively.

Conclusion

The immunoassay market continues to evolve through synergy among innovation, operational adaptability, and data-driven strategies. Stakeholders positioned for collaboration and technological advancement will capture the most value from this expanding sector.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.